- BGN21.00m
- BGN27.14m
- BGN15.82m
- 64
- 16
- 22
- 22
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.52 | ||
Price to Tang. Book | 2.53 | ||
Price to Free Cashflow | 40.54 | ||
Price to Sales | 1.33 | ||
EV to EBITDA | 22.39 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 2.67% | ||
Return on Equity | 1.08% | ||
Operating Margin | 2.11% |
Financial Summary
Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | BGNm | 7.67 | 11.72 | 6.75 | 11.2 | 15.82 | n/a | n/a | 18.66% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +166.67 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Etropal AD is a Bulgaria-based company, which specializes in the scientific research, experimental and development activities in the field of orthopedics and traumatology. The Company manufactures and offers endoprothesys and implants, special bioceramic materials and alloys for the medicine, special surgical instruments, osteosynthesys means, single use syringes, haemodialysis apparatuses and lines and single use medical materials. The Company’s product portfolio includes fiber dialyzers, arterial and venous lines for haemodialysis, transfusion and infusion sets, fistula and injection needles, catheters, tubes, and femoral implants, among others. The Company operates through one subsidiary, Etropal Trade OOD. As of December 31, 2011, the Company’s major shareholder was Sintetika AD with a stake of 66.53%.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 2nd, 1990
- Public Since
- November 7th, 2007
- No. of Employees
- 102
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Bulgarian Stock Exchange
- Shares in Issue
- 5,000,000

- Address
- bul. Ruski 191, ETROPOLE, 2180
- Web
- https://www.etropal.eu/
- Phone
- +359 72063422
- Auditors
- Emil Bozev
Upcoming Events for ETR
Similar to ETR
Bioiasis AD
Bulgarian Stock Exchange
Momina Krepost AD
Bulgarian Stock Exchange
FAQ
As of Today at 20:30 UTC, shares in Etropal AD are trading at BGN4.20. This share price information is delayed by 15 minutes.
Shares in Etropal AD last closed at BGN4.20 and the price had moved by -6.67% over the past 365 days. In terms of relative price strength the Etropal AD share price has underperformed the FTSE Global All Cap Index by -9% over the past year.
There is no consensus recommendation for this security.
Find out moreEtropal AD does not currently pay a dividend.
Etropal AD does not currently pay a dividend.
Etropal AD does not currently pay a dividend.
To buy shares in Etropal AD you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of BGN4.20, shares in Etropal AD had a market capitalisation of BGN21.00m.
Here are the trading details for Etropal AD:
- Country of listing: Bulgaria
- Exchange: BLG
- Ticker Symbol: ETR
Based on an overall assessment of its quality, value and momentum Etropal AD is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Etropal AD. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -0.13%.
As of the last closing price of BGN4.20, shares in Etropal AD were trading -22.59% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Etropal AD PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at BGN4.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Etropal AD's management team is headed by:
- Ivaylo Stoyanov - CHM
- Plamen Patev - CEO
- Rositsa Pencheva - CAO
- Maya Ivanova - DIR
- Nikolay Penchev - IND